Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.91Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: 0.87%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in FILSPARI sales and expansion approvals in Europe and the UK. The anticipation of approval for a new indication in FSGS is promising. However, financial challenges such as higher gross to net discounts and anticipated generic competition for Thiola present concerns. Despite the net loss, the company's financial performance showed improvement over the previous year.Company Guidance
During the Travere Therapeutics Q1 2025 earnings call, the company provided several key metrics showcasing strong performance and strategic progress. FILSPARI's net sales grew by 182% year-over-year and 13% quarter-over-quarter, reaching approximately $56 million in Q1 2025. Travere received 703 new patient start forms in the quarter, indicating robust demand. The company anticipates potential FDA approval for FILSPARI in FSGS by September, which could open a market of up to 30,000 addressable patients. Additionally, Travere reported total revenues of $81.7 million for the quarter, with a net loss of $41.2 million, or $0.47 per share. The company ended Q1 with $322.2 million in cash and marketable securities, bolstered by expected milestone payments from partners. Travere also highlighted the upcoming PDUFA date of August 28 for a submission to modify FILSPARI's REMS program, which could further enhance product convenience and patient access.FILSPARI Sales and Growth
Net sales for FILSPARI grew 182% year-over-year and 13% versus the prior quarter, reflecting strong demand and uptake. The drug achieved $56 million in net product sales in the first quarter.
European and UK Approval for FILSPARI
The European Commission and MHRA in the UK converted FILSPARI's conditional approvals to full approvals for the treatment of adults with IgA nephropathy.
sNDA Submission for FSGS
The company completed its submission for an sNDA for FILSPARI for the FSGS indication in March, expecting potential approval as early as September, marking a historic milestone as the first approved medication for FSGS.
Strong Financial Performance
The company generated net product sales of $75.9 million in the first quarter, representing 90% growth over the same period last year.
---
TVTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TVTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $20.76 | $21.15 | +1.88% |
Feb 20, 2025 | $23.58 | $21.98 | -6.79% |
Oct 31, 2024 | $17.76 | $17.50 | -1.46% |
Aug 01, 2024 | $9.24 | $9.00 | -2.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Travere Therapeutics (TVTX) report earnings?
Travere Therapeutics (TVTX) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Travere Therapeutics (TVTX) earnings time?
Travere Therapeutics (TVTX) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TVTX EPS forecast?
TVTX EPS forecast for the fiscal quarter 2025 (Q2) is -0.3.
---